RET and non-small cell lung carcinoma: Apatinib, a multi-kinase inhibitor targeting VEGFR and RET rearrangement is being tested in a single-arm phase II study (NCT02540824, PI: Cai-cun Zhou, Shanghai Pulmonary Hospital, China) that aims to determine the efficacy and safety in RET-fusion gene-positive NSCLC patients for whom previous treatment failed.